Search Results

You are looking at 1 - 8 of 8 items for :

  • "complexed PSA" x
Clear All
Full access

Yoshio Naya and Koji Okihara

1998 ; 44 : 1216 – 1223 . 17 Brawer MK Meyer GE Letran JL . Measurement of complexed PSA improves specificity for early detection of prostate cancer . Urology 1998 ; 52 : 372 – 378 . 18 Brawer MK Meyer GE Letran JL . Complexed

Full access

Rodger J. Winn

Oncologists take great pride in basing practice on the evidence that comes from well-designed trials. Critical appraisal of clinical data requires a firm grounding in the precepts of sound investigational methodology and a basic understanding of the underlying statistical analyses that lead to the conclusions drawn from a study. This knowledge base is further refined at professional meetings that facilitate critical commentaries. Clinical practice guidelines with texts that explain why a particular study did or did not change practice recommendations are another valuable means of developing analytic skills. This issue works to further sharpen these analytic skills, for example with the assessment from Rosenbaum et al. of the complex data surrounding the management of a post-therapeutic rising PSA and Ryan and Small's discussion of the multiple issues surrounding the use of hormonal therapy, including monotherapy or combined blockade, continuous or intermittent schedules, and the timing and duration of therapy. Moving on to some of the other articles, additional analytic skills are also necessary: – A solid understanding of the tools of clinical epidemiology are called into play in the article by Naya and Okihara on complexed PSA. Although the average oncologist may be comfortable with the definitions of sensitivity and specificity, the full implications of the positive predictive value of a test may be less clear, and the significance of a receiver operator curve (ROC) may be even more nebulous. – The Prostate Guideline is one of the first NCCN pathways to use a predictive nomogram1 in determining algorithm pathways...
Full access

T. PhD 5 2004 2 2 3 3 187 187 189 189 10.6004/jnccn.2004.0017 Prostate Early Detection Clinical Practice Guidelines in Oncology 5 2004 2 2 3 3 190 190 190 190 10.6004/jnccn.2004.0018 Role of Complexed PSA in the Early Detection of

Full access

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake and John T. Wei

prostate biopsy because they had a tPSA level within the “diagnostic gray zone” (i.e., 4–10 ng/mL). Complexed PSA: PSA exists in free and several complexed forms. Direct measurement of the complexed form (cPSA) with alpha-1-antichymotrypsin is now

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead and Maria Ho

Subong EN . Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer . Prostate Cancer Prostatic Dis 1998 ; 1 : 197 – 203 . 30. Bradley LA Palomaki GE Gutman S . Comparative effectiveness review

Full access

Michelle L. McDonald and J. Kellogg Parsons

. Prostate specific antigen testing among the elderly—when to stop? J Urol 2009 ; 181 : 1606 – 1614 ; discussion 1613–1614 . 49. Partin AW Brawer MK Subong EN . Prospective evaluation of percent free-PSA and complexed-PSA for early detection

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead and Deborah A. Freedman-Cass

. Partin AW Brawer MK Subong EN . Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer . Prostate Cancer Prostatic Dis 1998 ; 1 : 197 – 203 . 11. Bryant RJ Sjoberg DD Vickers AJ . Predicting

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead and Deborah Freedman-Cass

MK Subong EN . Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer . Prostate Cancer Prostatic Dis 1998 ; 1 : 197 – 203 . 126. Partin AW Brawer MK Bartsch G . Complexed prostate specific